MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04591nam a22004455i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
978-0-387-89520-8 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20160302164246.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
100301s2009 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780387895208 |
| -- |
978-0-387-89520-8 |
| 024 7# - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/978-0-387-89520-8 |
| Source of number or code |
doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
QR180-189.5 |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MJCM |
| Source |
bicssc |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MED044000 |
| Source |
bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
616.079 |
| Edition number |
23 |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Therapeutic Targets of the TNF Superfamily |
| Medium |
[electronic resource] / |
| Statement of responsibility, etc. |
edited by Iqbal S. Grewal. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
New York, NY : |
| Name of producer, publisher, distributor, manufacturer |
Springer New York, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2009. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XVII, 220 p. |
| Other physical details |
online resource. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| File type |
text file |
| Encoding format |
PDF |
| Source |
rda |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Advances in Experimental Medicine and Biology, |
| International Standard Serial Number |
0065-2598 ; |
| Volume/sequential designation |
647 |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Overview of TNF Superfamily: A Chest Full of Potential Therapeutic Targets -- Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges -- Targeting TNF for Treatment of Cancer and Autoimmunity -- Targeting of BAFF and APRIL for Autoimmunity and Oncology -- The Role of FasL and Fas in Health and Disease -- OX40 (CD134) and OX40L -- Targeting CD70 for Human Therapeutic Use -- 4-1BB as a Therapeutic Target for Human Disease -- RANK(L) as a Key Target for Controlling Bone Loss -- Targeting the LIGHT-HVEM Pathway -- GITR: A Modulator of Immune Response and Inflammation -- Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases -- Tumor Necrosis Factor Receptor Superfamily Member 21: TNFR-Related Death Receptor-6, DR6 -- TRAIL and Other TRAIL Receptor Agonists as Novel Cancer Therapeutics -- Therapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Tumor necrosis factor (TNF) superfamily is a rapidly growing family of cytokines that interacts with a corresponding superfamily of receptors. Ligand-receptor interactions of this superfamily are involved in numerous biological processes ranging from hematopoiesis to pleiotropic cellular responses, including activation, proliferation, differentiation, and apoptosis. The particular response depends on the receptor the cell type, and the concurrent signals received by the cell. Worldwide interest in the TNF field surged dramatically early in 1984 with the cloning and defining of the profound cellular effects of the first member of this family, TNFa. Subsequently, the major influence of TNFa on the development and functioning of the immune system was established. Today, over 20 human TNF ligands and their more than 30 corresponding receptors have been identified. Few receptors still remain orphans. What has emerged over the years is that most TNF ligands bind to one distinct receptor and some of the TNF ligands are able to bind to multiple TNF receptors, explaining to some extent the apparent disparity in the number of TNF receptors and ligands. Yet, in spite of some redundancy in TNF ligand/receptor interactions, it is clear that in vivo spatial, temporal, and indeed cell- and tissue-specific expression of both ligands and their receptors are important factors in determining the precise nature of cellular physiological and pathological processes they control. Therapeutic Targets of the TNF Superfamily presents the state-of-the art account on the role of TNF superfamily members in the pathogenesis and their use in current intervention of cancers and autoimmune disease. This text will be highly valuable for investigators to understand the disease processes regulated by TNF superfamily members and to develop effective therapeutics. A view into the future, inspired by the comprehensive work presented in this volume, predicts that researchers studying TNF superfamily members will continue to make rapid progress in identifying relevant components to the disease process and new therapeutic strategies to target many human diseases including cancers, autoimmune disease and others. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Immunology. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Biomedicine. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Immunology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Biomedicine general. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Grewal, Iqbal S. |
| Relator term |
editor. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Printed edition: |
| International Standard Book Number |
9780387895192 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Advances in Experimental Medicine and Biology, |
| International Standard Serial Number |
0065-2598 ; |
| Volume number/sequential designation |
647 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="http://dx.doi.org/10.1007/978-0-387-89520-8">http://dx.doi.org/10.1007/978-0-387-89520-8</a> |
| 912 ## - |
|---|
| -- |
ZDB-2-SBL |
